Skip to main content

Table 1 Characteristics of patients, their disease, and treatment

From: Outcomes of orbital malignancies treated with eye-sparing surgery and adjuvant particle radiotherapy: a retrospective study

Characteristic No. of patients (%)
Median age (range) 46.5 (14–74)
Sex
 Male 14 (63.6)
 Female 8 (36.4)
Tumor site
 Lacrimal gland 13 (59.1)
 Lacrimal sac 5 (22.7)
 Orbital bone 1 (4.5)
 Other 3 (13.6)
Tumor histology
 Adenoid cystic carcinoma 11 (50.0)
 Adenocarcinoma 5 (22.7)
 Squamous cells carcinoma 1 (4.5)
 Melanoma 1 (4.5)
 rhabdomyosarcoma 1 (4.5)
 desmoplastic small round cell tumor 1 (4.5)
 alveolar soft part sarcoma 1 (4.5)
 chondrosarcoma 1 (4.5)
T category
 T1 2 (9.1)
 T2 7 (31.8)
 T3 4 (18.2)
 T4 9 (40.9)
Tumor status
 Primary 21 (95.5)
 Recurrence 1 (4.5)
Surgical margin
 R0 3 (13.6)
 R1 6 (27.3)
 R2 or biopsy 13 (59.1)
Interval from surgery to radiotherapy, mo
 Median (range) 2.2 (1.2–6.13)
Radiotherapy technique
 PRT 1 (4.5)
 CIRT 18 (81.8)
 PRT + CIRT 3 (13.6)
Radiotherapy dose (Gy BED)
 Median (range) 85.05 (67.2–94.5)
GTV (ml)
 Median (range) 16.0 (1.9–67.6)
CTV (ml)
 Median (range) 43.4 (18.8–209.9)
Concurrent chemotherapy or immunotherapy
 Cisplatin 2 (9.1)
 Interferon α-2b 1 (4.5)
 No 19 (86.4)
\